Treatment of chemotherapy-refractory cancer in the advanced therapy access program

Molecular Therapy

Volumn 20, Issue 9, 2012, Pages 1654-1655

  Hemminki, Akseli ^a,b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b International Comprehensive Cancer Center Docrates   (Finland)

^c Oncos Therapeutics   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; ONCOLYTIC VIRUS;

ADVANCED CANCER; ADVANCED THERAPY ACCESS PROGRAM; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY REFRACTORY CANCER; CLINICAL PRACTICE; CLINICAL PROTOCOL; COMPUTER ASSISTED THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; EXPERIMENTAL THERAPY; GENETIC HETEROGENEITY; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; LETTER; MALIGNANT NEOPLASTIC DISEASE; ONCOLYTIC VIROTHERAPY; PATIENT CARE; PATIENT MONITORING; PEER REVIEW; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TRANSGENE; TREATMENT OUTCOME; ULTRASOUND THERAPY; VIRAL GENE THERAPY; VIRUS EXAMINATION; VIRUS REPLICATION;

EID: 84866981617     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.170     Document Type: Letter

References (10)

1. Cripe, TP (2012). Differing approaches to experimental therapeutics: are we a world apart? Mol Ther 20: 1649-1650.
2. Pesonen, S, Nokisalmi, P, Escutenaire, S, Särkioja, M, Raki, M, Cerullo, V et al. (2010). Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 17: 892-904
3. Cerullo, V, Pesonen, S, Diaconu, I, Escutenaire, S, Arstila, PT, Ugolini, M et al. (2010). Oncolytic adeno-virus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 70: 4297-4309.
4. Pesonen, S, Diaconu, I, Kangasniemi, L, Ranki, T, Kanerva, A, Pesonen, SK et al. (2012). Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 72: 1621-1631.
5. Koski, A, Kangasniemi, L, Escutenaire, S, Pesonen, S, Cerullo, V, Diaconu, I et al. (2010). Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 18: 1874-1884.
6. Nokisalmi, P, Pesonen, S, Escutenaire, S, Särkioja, M, Raki, M, Cerullo, V et al. (2010). Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res 16: 3035-3043.
7. Pesonen, S, Diaconu, I, Cerullo, V, Escutenaire, S, Raki, M, Kangasniemi, L et al. (2012). Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 130: 1937-1947.
8. Hemminki, O, Diaconu, I, Cerullo, V, Pesonen, SK, Kanerva, A, Joensuu, T et al. (2012). Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther 20: 1821-1830.
9. Cerullo, V, Diaconu, I, Kangasniemi, L, Rajecki, M, Escutenaire, S, Koski, A et al. (2011). Immunologi-cal effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 19: 1737-1746.
10. Koski, A, Raki, M, Nokisalmi, P, Liikanen, I, Kangas-niemi, L, Joensuu, T et al. (2012). Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther 20: 221-229.